$8.28
1.22% yesterday
NYSE, Jan 02, 10:00 pm CET
ISIN
CA23256X4075
Symbol
CYBN

Cybin Stock price

$8.28
+2.77 50.27% 1M
+0.90 12.20% 6M
+0.10 1.22% YTD
-1.13 12.01% 1Y
-3.01 26.66% 3Y
-44.54 84.32% 5Y
-41.36 83.32% 10Y
-41.36 83.32% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.10 1.22%
ISIN
CA23256X4075
Symbol
CYBN
Industry

Key metrics

Basic
Market capitalization
$403.5m
Enterprise Value
$349.5m
Net debt
positive
Cash
$86.4m
Shares outstanding
23.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.7
Financial Health
Equity Ratio
91.7%
Return on Equity
-
ROCE
-75.1%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-107.0m | $-85.8m
EBIT
$-107.3m | $-82.8m
Net Income
$-89.5m | $-75.3m
Free Cash Flow
$-76.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-71.1% | -
EBIT
-70.5% | -
Net Income
-56.8% | -
Free Cash Flow
-22.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.0
FCF per Share
$-3.3
Short interest
0.5%
Employees
-
Rev per Employee
-
Show more

Is Cybin a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Cybin Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cybin forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cybin forecast:

Buy
86%
Hold
14%

Financial data from Cybin

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 62 62
62% 62%
-
- Research and Development Expense 45 45
82% 82%
-
-107 -107
71% 71%
-
- Depreciation and Amortization 0.27 0.27
25% 25%
-
EBIT (Operating Income) EBIT -107 -107
71% 71%
-
Net Profit -89 -89
57% 57%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cybin directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cybin Stock News

Neutral
Business Wire
4 days ago
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the “ATM Program”) to allow Cybin to issue and sell up t...
Neutral
Business Wire
16 days ago
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American...
Neutral
Business Wire
16 days ago
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE America...

Company Profile

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Head office Canada
Website www.cybin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today